Chirfi Guindo's most recent trade in Beam Therapeutics Inc was a trade of 33,662 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 4, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Beam Therapeutics Inc | Chirfi Guindo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2025 | 33,662 | 33,662 | - | - | Stock Option (Right to Buy) | |
| Merck & Co Inc | Chirfi Guindo | Chief Marketing Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Apr 2025 | 26,867 | 26,867 | - | - | Stock Option (Right to Buy) | |
| Merck & Co Inc | Chirfi Guindo | Chief Marketing Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Apr 2025 | 5,902 | 5,902 | - | - | Restricted Stock Unit | |
| Merck & Co Inc | Chirfi Guindo | Chief Marketing Officer | Grant, award, or other acquisition of securities at price $ 97.94 per share. | 27 Jan 2025 | 28,158 | 69,143 (0%) | 0% | 97.9 | 2,757,795 | Common Stock |
| Beam Therapeutics Inc | Chirfi Guindo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Dec 2024 | 39,086 | 39,086 | - | - | Stock Option (Right to Buy) | |
| Merck & Co Inc | Chirfi Guindo | Chief Marketing Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 115.20 per share. | 05 Aug 2024 | 36,901 | 57,781 (0%) | 0% | 115.2 | 4,250,995 | Common Stock |
| Merck & Co Inc | Chirfi Guindo | Chief Marketing Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2024 | 36,901 | 36,903 | - | - | Restricted Stock Unit | |
| Merck & Co Inc | Chirfi Guindo | Chief Marketing Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 115.20 per share. | 05 Aug 2024 | 17,412 | 40,369 (0%) | 0% | 115.2 | 2,005,862 | Common Stock |
| Merck & Co Inc | Chirfi Guindo | Chief Marketing Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2024 | 29,297 | 29,297 | - | - | Stock Option (Right to Buy) | |
| Merck & Co Inc | Chirfi Guindo | Chief Marketing Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 105.70 per share. | 03 Aug 2023 | 36,901 | 38,341 (0%) | 0% | 105.7 | 3,900,436 | Common Stock |
| Merck & Co Inc | Chirfi Guindo | Chief Marketing Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Aug 2023 | 36,901 | 73,804 | - | - | Restricted Stock Unit | |
| Merck & Co Inc | Chirfi Guindo | Chief Marketing Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 105.70 per share. | 03 Aug 2023 | 17,989 | 20,352 (0%) | 0% | 105.7 | 1,901,437 | Common Stock |
| Merck & Co Inc | Chirfi Guindo | Chief Marketing Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2023 | 34,578 | 34,578 | - | - | Stock Option (Right to Buy) | |
| Biogen Inc | Chirfi Guindo | Head of Glob Prod Strat & Com | Other type of transaction at price $ 0.00 per share. | 18 Feb 2022 | 2,851 | 9,668 | - | - | Restricted Stock Unit | |
| Biogen Inc | Chirfi Guindo | Head of Glob Prod Strat & Com | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2022 | 1,981 | 8,243 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Chirfi Guindo | Head of Glob Prod Strat & Com | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2022 | 1,981 | 12,519 | - | - | Restricted Stock Unit | |
| Biogen Inc | Chirfi Guindo | Head of Glob Prod Strat & Com | Payment of exercise price or tax liability using portion of securities received from the company at price $ 209.79 per share. | 18 Feb 2022 | 879 | 7,364 (0%) | 0% | 209.8 | 184,405 | Common Stock |
| Biogen Inc | Chirfi Guindo | Head of Glob Prod Strat & Com | Other type of transaction at price $ 0.00 per share. | 12 Feb 2022 | 2,480 | 3,818 | - | - | Restricted Stock Unit | |
| Biogen Inc | Chirfi Guindo | Head of Glob Prod Strat & Com | Other type of transaction at price $ 0.00 per share. | 12 Feb 2022 | 2,395 | 0 | - | - | Restricted Stock Unit | |
| Biogen Inc | Chirfi Guindo | Head of Glob Prod Strat & Com | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2022 | 1,336 | 8,044 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Chirfi Guindo | Head of Glob Prod Strat & Com | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2022 | 1,336 | 6,298 | - | - | Restricted Stock Unit | |
| Biogen Inc | Chirfi Guindo | Head of Glob Prod Strat & Com | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2022 | 1,261 | 7,268 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Chirfi Guindo | Head of Glob Prod Strat & Com | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2022 | 1,261 | 2,395 | - | - | Restricted Stock Unit | |
| Biogen Inc | Chirfi Guindo | Head of Glob Prod Strat & Com | Payment of exercise price or tax liability using portion of securities received from the company at price $ 214.59 per share. | 12 Feb 2022 | 1,189 | 6,262 (0%) | 0% | 214.6 | 255,148 | Common Stock |
| Biogen Inc | Chirfi Guindo | Head of Glob Prod Strat & Com | Payment of exercise price or tax liability using portion of securities received from the company at price $ 214.59 per share. | 12 Feb 2022 | 593 | 7,451 (0%) | 0% | 214.6 | 127,252 | Common Stock |
| Biogen Inc | Chirfi Guindo | Head of Glob Prod Strat & Com | Payment of exercise price or tax liability using portion of securities received from the company at price $ 214.59 per share. | 12 Feb 2022 | 560 | 6,708 (0%) | 0% | 214.6 | 120,170 | Common Stock |
| Biogen Inc | Chirfi Guindo | Head of Glob Prod Strat & Com | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 9,090 | 9,090 | - | - | Restricted Stock Unit | |
| Biogen Inc | Chirfi Guindo | Head of Glob Prod Strat & Com | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2022 | 3,088 | 6,007 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Chirfi Guindo | Head of Glob Prod Strat & Com | Sale of securities on an exchange or to another person at price $ 440.00 per share. | 07 Jun 2021 | 3,087 | 2,919 (0%) | 0% | 440 | 1,358,280 | Common Stock |
| Biogen Inc | Chirfi Guindo | EVP Glob. Prod Strat and Comm | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2021 | 14,500 | 14,500 | - | - | Restricted Stock Unit | |
| Biogen Inc | Chirfi Guindo | EVP Glob. Prod Strat and Comm | Other type of transaction at price $ 0.00 per share. | 12 Feb 2021 | 2,194 | 7,634 | - | - | Restricted Stock Unit | |
| Biogen Inc | Chirfi Guindo | EVP Glob. Prod Strat and Comm | Other type of transaction at price $ 0.00 per share. | 12 Feb 2021 | 2,118 | 3,656 | - | - | Restricted Stock Unit | |
| Biogen Inc | Chirfi Guindo | EVP Glob. Prod Strat and Comm | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2021 | 1,622 | 9,828 | - | - | Restricted Stock Unit | |
| Biogen Inc | Chirfi Guindo | EVP Glob. Prod Strat and Comm | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2021 | 1,622 | 6,946 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Chirfi Guindo | EVP Glob. Prod Strat and Comm | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2021 | 1,534 | 5,774 | - | - | Restricted Stock Unit | |
| Biogen Inc | Chirfi Guindo | EVP Glob. Prod Strat and Comm | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2021 | 1,534 | 5,324 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Chirfi Guindo | EVP Glob. Prod Strat and Comm | Payment of exercise price or tax liability using portion of securities received from the company at price $ 278.03 per share. | 12 Feb 2021 | 477 | 6,006 (0%) | 0% | 278.0 | 132,620 | Common Stock |
| Biogen Inc | Chirfi Guindo | EVP Glob. Prod Strat and Comm | Payment of exercise price or tax liability using portion of securities received from the company at price $ 278.03 per share. | 12 Feb 2021 | 463 | 6,483 (0%) | 0% | 278.0 | 128,728 | Common Stock |
| Biogen Inc | Chirfi Guindo | EVP Glob. Prod Strat and Comm | Other type of transaction at price $ 0.00 per share. | 01 Dec 2020 | 693 | 0 | - | - | Restricted Stock Unit | |
| Biogen Inc | Chirfi Guindo | EVP Glob. Prod Strat and Comm | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2020 | 481 | 693 | - | - | Restricted Stock Unit | |
| Biogen Inc | Chirfi Guindo | EVP Glob. Prod Strat and Comm | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2020 | 481 | 4,004 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Chirfi Guindo | EVP Glob. Prod Strat and Comm | Payment of exercise price or tax liability using portion of securities received from the company at price $ 243.16 per share. | 01 Dec 2020 | 348 | 3,523 (0%) | 0% | 243.2 | 84,620 | Common Stock |
| Biogen Inc | Chirfi Guindo | EVP Glob. Prod Strat and Comm | Payment of exercise price or tax liability using portion of securities received from the company at price $ 243.16 per share. | 01 Dec 2020 | 214 | 3,790 (0%) | 0% | 243.2 | 52,036 | Common Stock |